Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2012 1
2013 2
2014 3
2015 8
2016 3
2017 4
2018 7
2019 2
2020 6
2021 6
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. DiNardo CD, et al. Among authors: willekens c. N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2. N Engl J Med. 2018. PMID: 29860938 Free article. Clinical Trial.
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS. Stein EM, et al. Among authors: willekens c. Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6. Blood. 2017. PMID: 28588020 Free PMC article. Clinical Trial.
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.
Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, Almire C, Hénon C, Kosmider O, Droin N, Rameau P, Catelain C, Alfaro A, Dussiau C, Friedrich C, Sourdeau E, Marin N, Szwebel TA, Cantin D, Mouthon L, Borderie D, Deloger M, Bredel D, Mouraud S, Drubay D, Andrieu M, Lhonneur AS, Saada V, Stoclin A, Willekens C, Pommeret F, Griscelli F, Ng LG, Zhang Z, Bost P, Amit I, Barlesi F, Marabelle A, Pène F, Gachot B, André F, Zitvogel L, Ginhoux F, Fontenay M, Solary E. Silvin A, et al. Among authors: willekens c. Cell. 2020 Sep 17;182(6):1401-1418.e18. doi: 10.1016/j.cell.2020.08.002. Epub 2020 Aug 5. Cell. 2020. PMID: 32810439 Free PMC article.
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
Maes T, Mascaró C, Tirapu I, Estiarte A, Ciceri F, Lunardi S, Guibourt N, Perdones A, Lufino MMP, Somervaille TCP, Wiseman DH, Duy C, Melnick A, Willekens C, Ortega A, Martinell M, Valls N, Kurz G, Fyfe M, Castro-Palomino JC, Buesa C. Maes T, et al. Among authors: willekens c. Cancer Cell. 2018 Mar 12;33(3):495-511.e12. doi: 10.1016/j.ccell.2018.02.002. Epub 2018 Mar 1. Cancer Cell. 2018. PMID: 29502954 Free article.
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia.
Selimoglu-Buet D, Wagner-Ballon O, Saada V, Bardet V, Itzykson R, Bencheikh L, Morabito M, Met E, Debord C, Benayoun E, Nloga AM, Fenaux P, Braun T, Willekens C, Quesnel B, Adès L, Fontenay M, Rameau P, Droin N, Koscielny S, Solary E; Francophone Myelodysplasia Group. Selimoglu-Buet D, et al. Among authors: willekens c. Blood. 2015 Jun 4;125(23):3618-26. doi: 10.1182/blood-2015-01-620781. Epub 2015 Apr 7. Blood. 2015. PMID: 25852055 Free PMC article. Clinical Trial.
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice.
Willekens C, Laplane L, Dagher T, Benlabiod C, Papadopoulos N, Lacout C, Rameau P, Catelain C, Alfaro A, Edmond V, Signolle N, Marchand V, Droin N, Hoogenboezem R, Schneider RK, Penson A, Abdel-Wahab O, Giraudier S, Pasquier F, Marty C, Plo I, Villeval JL, Constantinescu SN, Porteu F, Vainchenker W, Solary E. Willekens C, et al. Leukemia. 2023 Jun;37(6):1287-1297. doi: 10.1038/s41375-023-01878-0. Epub 2023 Apr 26. Leukemia. 2023. PMID: 37100881
Bortezomib and Waldenstrom's macroglobulinemia.
Pascal L, Gay J, Willekens C, Wemeau M, Balkaran S, Robu D, Roccaro A, Morel P, Ghobrial I, Leleu X. Pascal L, et al. Among authors: willekens c. Expert Opin Pharmacother. 2009 Apr;10(5):909-16. doi: 10.1517/14656560902800160. Expert Opin Pharmacother. 2009. PMID: 19351237 Review.
5-Azacitidine in patients with IDH1/2-mutant recurrent glioma.
Federici L, Capelle L, Annereau M, Bielle F, Willekens C, Dehais C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY, Idbaih A, Lemare F, de Botton S, Sanson M, Touat M. Federici L, et al. Among authors: willekens c. Neuro Oncol. 2020 Aug 17;22(8):1226-1228. doi: 10.1093/neuonc/noaa074. Neuro Oncol. 2020. PMID: 32215616 Free PMC article. No abstract available.
Linezolid induces ring sideroblasts.
Willekens C, Dumezy F, Boyer T, Renneville A, Rossignol J, Berthon C, Cotteau-Leroy A, Mehiaoui L, Quesnel B, Preudhomme C. Willekens C, et al. Haematologica. 2013 Nov;98(11):e138-40. doi: 10.3324/haematol.2013.092395. Haematologica. 2013. PMID: 24186315 Free PMC article. No abstract available.
45 results